(Q53513654)

15 May 2018

title

Health-related quality of life in patients with anaplastic astrocytoma during treatment with temozolomide. (English)

1 reference

15 May 2018

0 references

1 reference

0 references

anaplastic astrocytoma

1 reference

D Osoba

1

1 reference

15 May 2018

M Brada

series ordinal

2

1 reference

15 May 2018

W K Yung

series ordinal

3

1 reference

15 May 2018

M D Prados

series ordinal

4

1 reference

15 May 2018

publication date

1 September 2000

1 reference

15 May 2018

European Journal of Cancer

published in

1 reference

15 May 2018

volume

36

1 reference

15 May 2018

issue

14

1 reference

15 May 2018

page(s)

1788-1795

1 reference

15 May 2018

Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900165-9

7 January 2021

Modification of the EORTC QLQ-C30 (version 2.0) based on content validity and reliability testing in large samples of patients with cancer. The Study Group on Quality of Life of the EORTC and the Symptom Control and Quality of Life Committees of the

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900165-9

7 January 2021

The development and psychometric validation of a brain cancer quality-of-life questionnaire for use in combination with general cancer-specific questionnaires

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900165-9

7 January 2021

Effect of neurological dysfunction on health-related quality of life in patients with high-grade glioma.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900165-9

7 January 2021

The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900165-9

7 January 2021

Psychometric properties and responsiveness of the EORTC quality of Life Questionnaire (QLQ-C30) in patients with breast, ovarian and lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900165-9

7 January 2021

Testing the EORTC Quality of Life Questionnaire on cancer patients with heterogeneous diagnoses

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900165-9

7 January 2021

A validation study of the domains of the core EORTC quality of life questionnaire

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900165-9

7 January 2021

Interpreting the significance of changes in health-related quality-of-life scores.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900165-9

7 January 2021

The interpretation of scores from the EORTC quality of life questionnaire QLQ-C30.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900165-9

7 January 2021

Measurement of health status. Ascertaining the minimal clinically important difference

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900165-9

7 January 2021

Determining a minimal important change in a disease-specific Quality of Life Questionnaire.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900165-9

7 January 2021

Effect sizes for interpreting changes in health status.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900165-9

7 January 2021

10.1016/S0959-8049(00)00165-9

Identifiers

DOI

1 reference

15 May 2018

1 reference

15 May 2018